Tirzepatide

A dual GIP and GLP-1 receptor agonist developed by Eli Lilly. FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (weight management). Demonstrated greater weight loss than semaglutide in head-to-head trials.

What does Tirzepatide mean in peptide research?

A dual GIP and GLP-1 receptor agonist developed by Eli Lilly. FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (weight management). Demonstrated greater weight loss than semaglutide in head-to-head trials. This term is part of the broader field of peptide research, which encompasses both FDA-approved therapeutic peptides and research-grade compounds used in scientific investigation.

Why this term matters

Understanding Tirzepatide is foundational for anyone reviewing peptide research literature, comparing different research compounds, or following regulatory developments in this field. The term appears across pharmacology textbooks, FDA documentation, and clinical trial reports.

Where to learn more

For deeper context, see our peptide research articles:

• What Are Peptides? Comprehensive Introduction
• Research-grade vs Clinical-grade Peptides
• FDA Peptide Regulatory Status 2026
• Full Peptide Glossary Article